Suppr超能文献

2007 年至 2017 年瑞士丙型肝炎抗体检测频率和阳性率:一项回顾性纵向研究。

Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal study.

机构信息

Arud Centre for Addiction Medicine, Zurich, Switzerland.

Institute of Primary Care, University Hospital Zurich, University of Zurich, Switzerland.

出版信息

Swiss Med Wkly. 2023 Jun 5;153:40085. doi: 10.57187/smw.2023.40085.

Abstract

ACKGROUND AND AIMS

The prevalence of chronic hepatitis C in Switzerland is currently estimated at approximately 32,000 affected individuals (0.37% of the permanent resident population). An estimated 40% of affected individuals in Switzerland is undiagnosed. The Swiss Federal Office of Public Health requires laboratories to report all positive hepatitis C virus (HCV) test results. Approximately 900 newly diagnosed cases are reported annually. The number of HCV tests performed, however, is not collected by the Federal Office of Public Health and positive rates are therefore unknown. The aim of this study was to describe the longitudinal course of the numbers of hepatitis C antibody tests and of positive rates in Switzerland for the years 2007 to 2017.

METHODS

Twenty laboratories were asked to provide the number of HCV antibody tests performed and the number of positive antibody tests per year. Using data from the Federal Office of Public Health reporting system for the years 2012 to 2017, we calculated a factor to correct our values for multiple tests of the same person.

RESULTS

The annual number of HCV antibody tests performed tripled linearly from 2007 to 2017 (from 42,105 to 121,266) while the number of positive HCV antibody test results increased by only 75% over the same period (from 1360 to 2379). The HCV antibody test positive rate steadily decreased from 3.2% in 2007 to 2.0% in 2017. After correction for multiple tests per person, the person-level HCV antibody tested positive rate decreased from 2.2% to 1.7% from 2012 to 2017.

CONCLUSION

In the Swiss laboratories considered, more HCV antibody tests were performed each year in the period (2007-2017) before and during the approval of the new hepatitis C drugs. At the same time, the HCV antibody positive rates decreased, both on a per-test as well as a per-person level. This study is the first to describe the evolution of tests performed and of positive rates for HCV antibody in Switzerland at the national level over several years. In order to more accurately guide future measures to achieve the goal of eliminating hepatitis C by 2030, we recommend annual collection and publication of positive rates by health authorities, along with mandatory reporting of numbers of tests and people treated.

摘要

背景和目的

目前瑞士慢性丙型肝炎的患病率约为 32000 名受影响个体(占常住居民人口的 0.37%)。瑞士约 40%的受影响个体未被诊断。瑞士联邦公共卫生局要求实验室报告所有丙型肝炎病毒(HCV)阳性检测结果。每年约报告 900 例新诊断病例。然而,联邦公共卫生局并未收集 HCV 检测数量,因此阳性率未知。本研究旨在描述 2007 年至 2017 年瑞士 HCV 抗体检测数量和阳性率的纵向变化。

方法

要求 20 家实验室提供 HCV 抗体检测数量和每年阳性抗体检测数量。使用联邦公共卫生局报告系统 2012 年至 2017 年的数据,我们计算了一个因子,以校正我们对同一人多次检测的数值。

结果

2007 年至 2017 年,HCV 抗体检测数量每年呈线性三倍增长(从 42105 次增至 121266 次),而同期 HCV 抗体阳性检测结果仅增长 75%(从 1360 次增至 2379 次)。HCV 抗体检测阳性率从 2007 年的 3.2%稳步下降至 2017 年的 2.0%。校正每个人的多次检测后,2012 年至 2017 年,个体 HCV 抗体检测阳性率从 2.2%降至 1.7%。

结论

在所考虑的瑞士实验室中,在新丙型肝炎药物获得批准之前和期间(2007-2017 年),每年进行的 HCV 抗体检测数量增加。与此同时,检测数量和个体水平的 HCV 抗体阳性率均有所下降。本研究首次描述了瑞士全国范围内 HCV 抗体检测数量和阳性率在数年时间内的演变情况。为了更准确地指导未来实现到 2030 年消除丙型肝炎的目标的措施,我们建议卫生当局每年收集和公布阳性率,并强制报告检测数量和治疗人数。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验